ArticleFrontiers in pharmacology2026
Jaungo-based herbal complex regulates psoriasis-associated macrophage-keratinocyte inflammatory axis.
Article in Frontiers in pharmacology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background/Objectives: Psoriasis is a chronic inflammatory skin disease characterized by dysregulated cross-talk between macrophages and keratinocytes, resulting in excessive cytokine signaling and impaired epidermal barrier function. Traditional Jaungo has long been used as a topical remedy for inflammatory skin disorders, and its core herbal components exhibit well-documented anti-inflammatory and tissue-protective properties. This study aimed to develop a Jaungo-based herbal complex (JBHC) and evaluate its effects on macrophage-mediated inflammatory responses and keratinocyte barrier dysfunction under psoriasis-like conditions. Methods: Publicly available transcriptomic datasets were analyzed to identify inflammatory and barrier-related gene expression patterns in psoriatic lesions. The anti-inflammatory effects of JBHC were assessed in LPS-stimulated RAW264.7 macrophages by analyzing the expression of inflammatory mediators and signaling pathways. To evaluate macrophage-keratinocyte cross-talk, conditioned media from activated macrophages, with or without JBHC treatment, were applied to keratinocytes, followed by analysis of epidermal barrier gene expression. Results: Transcriptomic analyses revealed consistent upregulation of inflammatory cytokines and chemokines, accompanied by significant suppression of key epidermal barrier genes in psoriatic lesions. JBHC markedly attenuated LPS-induced inflammatory signaling in RAW264.7 macrophages by downregulating NOS2, PTGS2, and multiple cytokine genes, while selectively modulating STAT1/STAT3 activation. Conditioned media from activated macrophages significantly suppressed the expression of filaggrin (FLG) and loricrin (LOR) in keratinocytes; however, conditioned media from JBHC-treated macrophages effectively mitigated this barrier gene suppression. Conclusion: JBHC modulates macrophage-mediated inflammatory pathways and protects keratinocyte barrier gene expression under psoriasis-like inflammatory conditions. These findings suggest that JBHC has potential as a functional herbal complex targeting the macrophage-keratinocyte inflammatory axis in chronic inflammatory skin diseases such as psoriasis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.